Novartis announces clinical collaboration with Pfizer to advance the treatment of NASH

  • Agreement includes a clinical trial to evaluate a combination of tropifexor (LJN452) and one or more Pfizer compounds for the treatment of non-alcoholic steatohepatitis (NASH)
     
  • Novartis has a leading development portfolio in non-viral liver diseases, including NASH
     
  • There are currently no approved treatments for NASH, a progressive form of non-alcoholic fatty liver disease, which affects up to 6.5% of the population worldwide ,-

The digital press release with multimedia content can be accessed here:

Basel, October 29, 2018 - Novartis announced today that it has entered into a clinical development agreement with Pfizer which will include a study combining tropifexor and one or more Pfizer compounds for the treatment of NASH, including an Acetyl CoA-Carboxylase (ACC) Inhibitor (PF-05221304, a Diacylglycerol O-Acyltransferase 2 (DGAT2) Inhibitor (PF-06865571, and a Ketohexokinase (KHK) Inhibitor (PF-06835919). The financial details of this transaction are not disclosed.

"Novartis has a leading development portfolio in non-viral liver diseases and I believe especially in our combination therapies. Liver diseases, including NASH, are multifaceted with various factors that contribute to the progression of the disease. This makes them difficult to treat with a single compound," said Eric Hughes, Global Development Unit Head, Immunology, Hepatology and Dermatology. "We want to collaborate with multiple partners to drive the science and understanding of how to treat non-viral liver diseases. Targeting different pathways in NASH with a broad array of therapies is an essential strategy to bring the best treatments to patients.

NASH is a complex condition with no currently available treatment options. NASH presents a high unmet patient need, as it affects up to 6.5% of the population worldwide, and is largely asymptomatic , . As fat builds up in the liver, it can trigger a vicious cycle of chronic inflammation and liver scarring called fibrosis. Over time, liver inflammation and fibrosis may progress to cirrhosis, which can lead to liver failure and death , .

About tropifexor (LJN452)
Novartis is developing a Farnesoid X receptor (FXR) agonist for the treatment of NASH. The non-bile acid FXR agonist, tropifexor, is an oral treatment designed to address several features of NASH including; the buildup of fat in the liver, inflammation and fibrosis. Early studies with tropifexor in animal models have shown reduction in fat accumulation in the liver (steatosis), inflammation, and scarring, alongside a favorable safety profile. In Oct 2016, tropifexor was granted Fast Track designation by the US FDA for NASH with liver fibrosis.


This site uses cookies and analysis tools to improve the usability of the site. More information. |